Ajinomoto And Kyoto Team Develop iPS Cell Culture Medium StemFit
This article was originally published in PharmAsia News
Ajinomoto and Kyoto University’s Center for iPS Cell Research and Application have developed StemFit, a new iPS cell medium made up of a balance of amino acids, sugars, lipids, growth factors that does not contain animal/human-derived components
You may also be interested in...
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.
Coronavirus Notebook: EMA Data Hack Aimed At 'Undermining Trust' In Vaccines, Russia Plans EU Sputnik V Filing Next Month
France has reported on side-effect reports concerning the Pfizer/BioNTech vaccine, and the World Health Organization has warned that plans to provide global equitable access to coronavirus vaccines are at risk.